# Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

Source: https://onco.cc/trials/nct06635785/  
OnCo record `nct06635785` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AI-081 in advanced solid tumours, run by OncoC4, Inc., now recruiting.

## Summary

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06635785 by OncoC4, Inc., with 387 participants planned, started 2025-03-26 and due to reach its primary completion in 2027-06-30. Interventions recorded: AI-081.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06635785
- Phase: 1/2
- Setting: Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
- Sponsor: OncoC4, Inc.
- Enrolled: 387

## Sources

- ClinicalTrials.gov NCT06635785: https://clinicaltrials.gov/study/NCT06635785

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [AI-081](https://onco.cc/drugs/ai-081/)
- companies: [OncoC4](https://onco.cc/companies/oncoc4/)

---
JSON: https://onco.cc/api/v1/entities/nct06635785.json